Thyroid nodular disease represents a common endocrine condition frequently encountered in ENT outpatient settings. Increased utilization of high-resolution ultrasonography has led to higher detection rates of thyroid nodules in recent years [1,2]. Although the majority of nodules are non-neoplastic, approximately 5–15% may harbor malignancy, necessitating systematic evaluation [3]. Thyroid disorders predominantly affect females and are commonly diagnosed during the third to fifth decades of life [4]. Various etiological factors including iodine imbalance, radiation exposure, and genetic susceptibility contribute to thyroid enlargement and nodular transformation [5]. Clinical manifestations range from painless anterior neck swelling to compressive symptoms such as dysphagia or voice changes in advanced cases [6]. The principal aim of assessment is to differentiate benign from malignant lesions to guide appropriate management [7]. FNAC is widely accepted as a first-line diagnostic tool because of its safety, affordability, and diagnostic reliability [8]. The Bethesda System has improved standardization and risk stratification of thyroid cytology [9]. However, cytology has limitations, particularly in follicular-pattern lesions where capsular or vascular invasion can only be confirmed histologically [10]. Given regional variations in disease patterns, institutional clinicopathological studies are important to evaluate diagnostic concordance and local epidemiology. This study was therefore conducted to assess the clinical profile and cytological-histopathological correlation of thyroid swellings presenting to a tertiary ENT department.

Materials and Methods

This cross-sectional observational study was conducted in the Department of ENT at a tertiary care hospital over a period of 24 months. Institutional ethical approval was obtained and informed consent was secured from all participants.

Inclusion criteria

• All consecutive patients presenting to the ENT outpatient department with clinically palpable thyroid swelling (solitary nodule, multinodular goitre or diffuse enlargement) during the study period.
• Age ≥ 12 years.
• Patients who underwent FNAC; those undergoing surgery had histopathological examination.

Exclusion criteria

• Patients with purely lateral neck masses not arising from the thyroid.
• Patients with known prior thyroid malignancy under follow-up.
• Patients declining FNAC or consent for participation.
• Inadequate cytology samples despite repeat FNAC (for FNAC-HPE correlation analysis, only adequate samples were included).

Clinical evaluation

Detailed history and clinical examination were recorded (duration, pain, rapid enlargement, pressure symptoms, hoarseness, family history, radiation exposure). Thyroid function tests (T3, T4, TSH) and neck ultrasound (size, echotexture, suspicious features) were performed as per departmental protocol. FNAC was performed under palpation or ultrasound guidance dependent on nodule characteristics.

FNAC and histopathology

FNAC was reported by experienced cytopathologists using local institutional criteria (and where available Bethesda categories). Surgical specimens were processed with routine H&E staining and diagnosed per WHO criteria. For analysis, FNAC diagnoses were categorized into benign, suspicious/indeterminate (including follicular neoplasm/AUS), and malignant.

Statistical analysis

Data were analyzed using SPSS version 25. Continuous variables were expressed as mean ± standard deviation, and categorical variables as frequencies and percentages. Diagnostic indices of FNAC were calculated using histopathology as the gold standard. Statistical significance was set at p < 0.05.

RESULTS

A total of 150 patients with thyroid swelling were included. Mean age was 38.7 ± 12.4 years (range 13–76); 135 (90%) were female and 15 (10%) male. Duration of swelling averaged 2.1 ± 1.6 years. Presenting complaints: cosmetic swelling (85%), pressure symptoms (18%), dysphagia (8%), hoarseness (3%). Thyroid function: euthyroid in 138 (92%), hypothyroid in 9 (6%), hyperthyroid in 3 (2%).

Table 1: Age and sex distribution

Multinodular goitre was the most common clinical presentation (70 cases, 46.7%), followed by solitary thyroid nodule (60 cases, 40%). Diffuse goitre was observed in 10 cases (6.7%), and 10 patients (6.6%) presented with suspicious neck masses or cervical lymphadenopathy. Out of total 120 (80%) underwent surgical management, while 30 (20%) were managed conservatively.

Table 2: Clinical types and surgery performed

Of the 90 cases reported as benign on FNAC, 86 were benign and 4 were malignant on histopathology. Among the 16 indeterminate/suspicious cases (AUS/follicular neoplasm), 10 were benign and 6 were malignant on histopathology, whereas 14 cases diagnosed as malignant on FNAC, 12 were confirmed malignant and 2 were benign on histopathology

Table 3: FNAC vs Histopathology (n = 120 operated cases)

Among the 120 operated cases, 98 (81.7%) were histopathologically benign and 22 (18.3%) were malignant

Table 4: Histopathological distribution (n = 120)

Among FNAC findings 80% cases reported as benign, 12% inderminate and 8% were malignant

Graph 1: FNAC diagnostic categories among study participants

DISCUSSION

The findings of this cross-sectional study conducted in an ENT setting are in agreement with existing literature, demonstrating that thyroid swellings are more frequently observed in middle-aged females and are predominantly benign in nature, with papillary carcinoma representing the most common malignant entity [11]. The marked female preponderance and concentration of cases within the third to fifth decades of life in our series parallel observations from multiple tertiary care studies conducted in India and other regions, which report a female-to-male ratio ranging from 4:1 to 10:1 [12,13]. Fine-needle aspiration cytology continues to serve as a valuable diagnostic modality, particularly due to its high specificity. Published meta-analyses and institutional experiences indicate that the diagnostic performance of FNAC improves when combined with ultrasound guidance and standardized reporting systems such as the Bethesda classification [14]. Despite its utility, FNAC has inherent diagnostic constraints, especially in follicular-pattern lesions. Differentiation between follicular adenoma and follicular carcinoma requires demonstration of capsular or vascular invasion on histopathological examination, which cannot be reliably assessed cytologically. This limitation was reflected in our indeterminate FNAC cases, where final histopathology revealed both benign and malignant outcomes [15]. Ultrasonography played an important role in risk assessment by identifying suspicious sonographic features and facilitating targeted aspiration of nodules, thereby enhancing diagnostic accuracy [16]. The sensitivity, specificity, and predictive values observed in our study fall within the range reported in contemporary literature, where FNAC accuracy typically varies between 80% and 95% in centers utilizing ultrasound-guided sampling and standardized cytological reporting [17]. From a clinical management perspective, patients with benign cytology and non-suspicious imaging findings can generally be managed conservatively, whereas those with malignant or strongly suspicious cytology warrant definitive surgical intervention. Indeterminate cytological categories remain diagnostically challenging. Although molecular diagnostic techniques may improve risk stratification, their availability is limited in many institutions, and surgical excision continues to be the preferred approach for definitive diagnosis and treatment in such cases [18]. The present study has certain limitations, including its single-center design and possible referral bias, as histopathological confirmation was available only for surgically treated cases. Additionally, the relatively small number of rare malignancies limits subgroup analysis. Nevertheless, the study contributes meaningful regional clinicopathological data and reinforces the importance of integrated clinical, cytological, and histopathological evaluation in the management of thyroid swellings within ENT practice.

CONCLUSION

Thyroid swellings encountered in ENT practice are predominantly benign and show a strong female preponderance. FNAC offers reliable preoperative assessment with high specificity and acceptable sensitivity, particularly when interpreted alongside ultrasonographic findings. However, histopathological examination remains essential for definitive diagnosis, especially in indeterminate lesions. A structured clinic radiological and cytological approach enhances diagnostic accuracy and optimizes surgical decision-making.

REFERENCES

1. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high-frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009; 39(8):699-706. doi:10.1111/j.1365-2362.2009.02162.x
2. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The natural history of benign thyroid nodules. JAMA. 2015; 313(9):926-935. doi:10.1001/jama.2015.0956
3. Vanderpump MPJ. The epidemiology of thyroid disease. Br Med Bull. 2011; 99(1):39-51. doi:10.1093/bmb/ldr030
4. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015; 3(4):286-295. doi:10.1016/S2213-8587(14)70225-6
5. Burch HB, Burman KD, Cooper DS, et al. A 2011 survey of clinical practice patterns in the management of thyroid nodules. J Clin Endocrinol Metab. 2012; 97(4):1179-1185. doi:10.1210/jc.2011-3050
6. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26(1):1-133. doi:10.1089/thy.2015.0020
7. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules—2016 update. Endocr Pract. 2016; 22(5):622-639. doi:10.4158/EP161208.GL
8. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017; 27(11):1341-1346. doi:10.1089/thy.2017.0500
9. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: A meta-analysis. Acta Cytol. 2012; 56(4):333-339. doi:10.1159/000339959
10. Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging Reporting and Data System (TI-RADS): White paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017; 14(5):587-595. doi:10.1016/j.jacr.2017.01.046
11. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008; 22(6):901-911. doi:10.1016/j.beem.2008.09.005
12. Kumar N, Ray C, Jain S. Clinicopathological evaluation of thyroid swellings: A tertiary care centre experience. Indian J Otolaryngol Head Neck Surg. 2016; 68(2):173-178. doi:10.1007/s12070-015-0931-4
13. Daimary M, Lynrah KG, Syiemlieh J. Clinicopathological spectrum of thyroid swellings in a tertiary care centre. Asian Pac J Cancer Care. 2023; 8(1):51-56. doi:10.31557/APJCC.2023.8.1.51
14. Tee YY, Lowe AJ, Brand CA, Judson RT. Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: A comprehensive literature review. Ann Surg. 2007; 246(5):714-720. doi:10.1097/SLA.0b013e3180f61adc
15. Lloyd RV, Osamura RY, Klöppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.
16. Remonti LR, Kramer CK, Leitão CB, Pinto LC, Gross JL. Thyroid ultrasound features and risk of carcinoma: A systematic review and meta-analysis. Thyroid. 2015; 25(5):538-550. doi:10.1089/thy.2014.0353
17. Singh Ospina N, Maraka S, Espinosa De Ycaza AE, et al. Diagnostic accuracy of ultrasound-guided fine needle aspiration biopsy for thyroid malignancy: Systematic review and meta-analysis. Endocrine. 2016; 53(3):651-661. doi:10.1007/s12020-016-0976-1
18. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma. JAMA Oncol. 2016; 2(8):1023-1029. doi:10.1001/jamaoncol.2016.0386

Study Design and Setting

This was a cross-sectional observational study conducted in the Department of General Surgery, Government Medical College, Thiruvananthapuram, over a period of one year. The study was initiated after obtaining clearance from the Human Ethics Committee Trivandrum Medical College (HEC NO:04/21/2023/MCT), adhering to all ethical principles and guidelines for human research.

Study Population and Sampling

The study included adult patients aged 18 years and above with radiologically confirmed isolated traumatic brain injury (TBI) who were admitted within 24 hours of trauma. “Isolated TBI” was defined as brain injury without evidence of other systemic injuries. Patients with traumatic injuries to other organs, known pre-existing coagulopathies, use of anticoagulant drugs, chronic liver disease, diabetes mellitus, systemic hypertension, or sepsis were excluded to reduce confounding variables. A total of 144 participants were enrolled using a consecutive sampling method until the desired sample size was reached. The sample size was calculated based on a prior reported prevalence of coagulopathy in isolated TBI (46%) with a 95% confidence level and 20% relative precision.

Data Collection Tools and Definitions

A structured and pre-tested proforma was used to collect data on demographic characteristics, mechanism and type of injury, Glasgow Coma Scale (GCS) score, pupil reactivity, and CT imaging findings. Laboratory investigations including complete blood count, coagulation profile (prothrombin time [PT], activated partial thromboplastin time [APTT], international normalized ratio [INR], platelet count), arterial blood gas analysis (including pH), haemoglobin, and random blood glucose levels were performed within 12 hours of admission. Coagulopathy was operationally defined as the presence of one or more of the following: PT >14 seconds, APTT >36 seconds, INR >1.25, or platelet count <1 lakh/μL. These thresholds were based on institutional norms and previously published literature.

Exposure and Outcome Variables

The primary exposure variable was the presence or absence of coagulopathy. The primary outcome was in-hospital mortality. Secondary outcomes included associations of coagulopathy with clinical parameters such as GCS score at admission, pupil responsiveness, haemoglobin levels, and acid-base status (pH).

Management Protocol and Follow-up

All patients were managed according to institutional head injury protocols, including neuroimaging, monitoring of vital signs, and supportive measures. Most patients received tranexamic acid as per the CRASH-3 protocol for TBI, a limitation noted due to its influence on fibrinolytic mechanisms. Patients were followed up from the time of admission until discharge or in-hospital death. Data on clinical course, need for neurosurgical intervention, and outcome were collected during hospital stay.

Statistical Analysis

Data entry was carried out using Microsoft Excel and analyzed using IBM SPSS version 27.0. Descriptive statistics were applied to summarize baseline characteristics. Categorical variables were reported as frequencies and percentages, while continuous variables were expressed as mean and standard deviation. The Chi-square test was used to determine associations between coagulopathy and categorical variables like mortality, GCS category, and pupil response. For normally distributed continuous variables such as haemoglobin and pH, Student’s t-test was applied; otherwise, the Mann-Whitney U test was used. A p-value of less than 0.05 was considered statistically significant, and p<0.01 was considered highly significant.

Ethical Considerations

Written informed consent was obtained from all participants or their legal guardians in cases of altered sensorium or impaired consciousness. Confidentiality of patient data was strictly maintained, and participation in the study did not affect the course of clinical management. No additional investigations or financial burdens were imposed on patients as all tests were part of standard clinical care. The results of the study were used solely for academic and research purposes

The study included 144 patients with isolated traumatic brain injury (TBI). The majority of traumatic brain injury (TBI) patients in the study belonged to the age group of 18–30 years (31.9%), reflecting the high-risk behaviour and increased exposure to road traffic accidents in younger adults. The mean age of the sample was 43.4 ± 19.3 years, suggesting a relatively younger to middle-aged population affected by TBI. Regarding sex distribution, there was a marked male predominance (85.4%), consistent with global trends indicating higher risk-taking behaviours and occupational exposure among men (Table 1). Among the 144 patients with traumatic brain injury (TBI), road traffic accidents (RTAs) emerged as the leading cause, accounting for 78.5% of cases. This underscores the significant public health impact of motor vehicle-related injuries. Assault (11.8%) and slip and fall incidents (7.6%) were other notable contributors, while giddiness-related falls (2.8%) were more common among the elderly population, suggesting age-related balance issues or underlying comorbidities. These findings emphasize the importance of improving road safety measures and fall prevention strategies, particularly in vulnerable age groups (Figure 1). The majority of TBI cases (61.1%) presented with extra-parenchymal injuries, including subdural hematoma (SDH), epidural hematoma (EDH), and subarachnoid hemorrhage (SAH), which are commonly associated with blunt trauma and acceleration-deceleration mechanisms. Intra-parenchymal injuries, such as contusions and intraparenchymal hemorrhage, were noted in 16.7% of the patients. Notably, 20.8% had combined extra- and intra-parenchymal hemorrhages, indicating more severe or diffuse brain trauma. A minority (1.4%) presented with pneumocephalus, likely secondary to basal skull fractures or open cranial injuries (Figure 2).

 Among the 144 patients with traumatic brain injury (TBI), 20.1% had an elevated INR (>1.25), indicating the presence of coagulopathy at admission. The majority of patients (79.9%) had INR values within the normal range (≤1.25). An increased INR reflects impaired extrinsic pathway function, which may predispose to or worsen intracranial bleeding (Table 2).

Among the coagulation parameters, 20.1% of patients exhibited an elevated INR (>1.25), while 23.6% had a prolonged prothrombin time (PT >14s), both indicating significant disruption in the extrinsic coagulation pathway. Although activated partial thromboplastin time (APTT >36s) was elevated in only 8.3% of patients, its presence still contributed to the overall coagulopathy profile. Thrombocytopenia (platelet count <1 lakh/µL) was observed in 11.1%, which is clinically important as platelets play a central role in clot formation and prevention of progressive intracranial hemorrhage. Anemia (Hb ≤10 g/dL) and metabolic acidosis (pH ≤7.2) were each noted in 8.3% of patients, both of which were statistically associated with coagulopathy in this cohort. These findings support the interplay between tissue hypoxia, systemic shock, and impaired coagulation mechanisms. From a neurological standpoint, 9% of patients presented with severe TBI (GCS <8), and this group had a high prevalence of coagulopathy, consistent with previous studies linking injury severity to haemostatic dysfunction. Additionally, abnormal pupillary findings were seen in 10.4% of patients 6.9% with anisocoria and 3.5% with absent reactivity suggesting elevated intracranial pressure or brainstem dysfunction (Table 3).

Out of 144 patients with isolated traumatic brain injury (TBI), 90.3% were successfully discharged, while 9.7% died during their hospital stay. Although the majority of patients recovered, the in-hospital mortality rate of nearly 10% underscores the severity of isolated TBI and its potentially fatal complications. Mortality was observed to be significantly associated with coagulopathy, particularly among patients with elevated INR, prolonged PT, thrombocytopenia, metabolic acidosis, low GCS scores, and abnormal pupillary response. These findings suggest that early identification and correction of these derangements could be crucial in reducing preventable TBI deaths (Figure 3). Among those without coagulopathy, all 87 patients (100%) were discharged, and none expired. In contrast, among patients with coagulopathy, 24.6% died while receiving intensive care, and only 75.4% were discharged. The chi-square test yielded a χ² value of 23.67 with a p-value < 0.01, indicating that the difference in outcomes between patients with and without coagulopathy is highly statistically significant. This confirms that coagulopathy is a strong predictor of adverse outcome in isolated TBI and should be used as a critical early marker in patient triage and management decisions (Figure 4).

Clinical and laboratory variables revealed significant associations between coagulopathy and several risk factors in patients with isolated traumatic brain injury (TBI). Among the variables studied, Glasgow Coma Scale (GCS) showed a strong inverse relationship with coagulopathy. While only 30.8% of patients with mild TBI (GCS 13–15) had coagulopathy, the proportion increased to 72.7% in those with moderate TBI (GCS 8–13) and peaked at 92.3% among patients with severe TBI (GCS <8). This trend was statistically significant (χ² = 24.01, p < 0.01), indicating that lower GCS scores at presentation are strongly predictive of coagulation abnormalities. Similarly, arterial pH showed a meaningful association with coagulopathy. Patients with metabolic acidosis (pH ≤7.2) had an 83.3% prevalence of coagulopathy compared to only 35.6% among those with normal pH values (>7.2), a difference that was highly significant (χ² = 10.48, p = 0.001). Haemoglobin levels also correlated significantly with the presence of coagulopathy; 75% of patients with anaemia (Hb ≤10 g/dL) exhibited coagulopathy, compared to 36.4% in those with normal haemoglobin levels, with statistical significance (χ² = 6.87, p = 0.009) (Table 4).

Traumatic brain injury (TBI) remains a leading global cause of mortality and morbidity, particularly among young adults. Sixty-nine million (95% CI 64-74 million) individuals worldwide are estimated to sustain a TBI each year. The proportion of TBIs resulting from road traffic collisions was greatest in Africa and Southeast Asia (both 56%) and lowest in North America (25%) (15). It is acknowledged that 12% of all deaths in India are caused by injuries and the resulting deaths, which constitute a public health concern (16). The eighth most common cause of mortality worldwide and the top cause of death for youths between the ages of 15 and 29 is road traffic injuries (RTI). 2. Unless immediate action is taken, current trends indicate that traffic-related deaths will rank as the fifth most common cause of death by 2030 (17).

Our study contributes to the existing literature by examining the prevalence of coagulopathy and its impact on clinical outcomes in patients with isolated TBI admitted to a tertiary care center in Kerala.

Several studies from high-income countries have recommended using coagulation markers such as PT, APTT, INR, platelet count, and thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to identify patients at risk for poor outcomes (17,18). However, these advanced tests are not widely available in most Indian tertiary centers. Our study adopts practical and commonly available laboratory parameters to assess coagulopathy. Defining coagulopathy as PT >14 seconds, APTT >36 seconds, INR >1.25, or platelet count <1 lakh/µL, this investigation seeks to provide data relevant to routine clinical settings. Additionally, it evaluates associated clinical predictors such as Glasgow Coma Scale (GCS), pupillary response, pH, and haemoglobin levels to understand the risk factors contributing to coagulopathy. A key finding of our study was the significant association between coagulopathy and in-hospital mortality. Among patients without coagulopathy, no deaths were recorded, whereas 24.6% of coagulopathic patients died during hospitalization. Another study stated the similar finding where coagulopathy is a strong independent predictor of mortality in TBI patients (6,13). According to some studies, the mechanism might entail diminished cerebral perfusion, elevated intracranial pressure, and progressive haemorrhagic damage (12).

The factors that contribute to the development of coagulopathy were also examined in the study. The Glasgow Coma Scale (GCS) score showed a strong negative connection with coagulopathy. The prevalence of coagulopathy increased significantly to 72.7% in moderate TBI cases and 92.3% in severe TBI cases, whereas it was only 30.8% in mild TBI patients. This result is consistent with other studies where they stated that systemic coagulation abnormalities are caused by the activation of inflammatory and endothelial pathways as the severity of brain injury increases [3,4]. Acidosis (pH ≤7.2) was another important factor linked with coagulopathy. Our study found that 83.3% of patients with acidosis developed coagulopathy, a statistically significant finding. This supports the widely accepted concept of the "lethal triad" in trauma acidosis, coagulopathy, and hypothermia – which together significantly worsen outcomes (11-16). Similarly, anemia (Hb ≤10 g/dL) was found in 75% of patients with coagulopathy, compared to only 36.4% in non-coagulopathic patients. This highlights how reduced oxygen delivery may exacerbate secondary brain injury and impair hemostasis (7).

APTT abnormalities were present in only 8.3% of the cohort, their presence alongside elevated PT and INR reinforces the need for a comprehensive coagulation profile upon admission. Some studies have similarly stressed the importance of evaluating both intrinsic and extrinsic coagulation pathways in TBI patients (10,11). Also, studies have proved thrombocytopenia correlates with poor neurological outcomes in head injury (14,16,18). Our study also supports the recommendation of early correction of coagulation abnormalities in neurosurgical and trauma patients to prevent deterioration (17,21).

However, our study has several limitations. First, it was conducted in a single tertiary care center, which may limit generalizability. Second, the observational design precludes causal inference. Third, advanced coagulation diagnostics such as thromboelastography (TEG) were not available, which could have provided a more dynamic understanding of coagulation status. Also, the use of tranexamic acid based on CRASH-3 protocol in most patients may have influenced the natural progression of coagulopathy, potentially masking its full impact. Finally, we did not assess long-term functional outcomes post-discharge, which could offer more comprehensive insight into the burden of TBI-related coagulopathy. Despite these limitations, the study highlights the high prevalence and prognostic value of coagulopathy in isolated TBI, and underscores the importance of integrating basic coagulation tests such as PT, INR, APTT, hemoglobin, and pH in routine evaluation. These markers, along with clinical indicators like GCS and pupillary response, can guide early intervention strategies and improve patient outcomes.

In conclusion, this study has provided valuable insights into the prevalence of coagulopathy among isolated TBI patients admitted to a tertiary care centre and its implications for patient outcomes. Coagulopathy is a common and clinically significant complication in patients with isolated TBI. It is strongly associated with poor outcomes, including in-hospital mortality. Early identification and correction of coagulation abnormalities, particularly in patients with low GCS, acidosis, or anemia, can be crucial in reducing TBI-related morbidity and mortality. Further multicentric studies with long-term follow-up and advanced diagnostics are warranted to develop standardized protocols for managing TBI-associated coagulopathy.

DECLARATIONS

Conflicts of interest: The authors declare that they have no conflicts of interest.

Source of funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval: The study was approved by the Human Ethics Committee of Government Medical College Thiruvananthapuram (HEC NO:04/21/2023/MCT).

Consent to participate: Written informed consent was obtained from all participants or their legally authorized representatives.

Consent for publication: Informed consent for publication was obtained from all participants.

Availability of data and material: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contribution:

• AS: Conceptualization, Study design, Data collection, Drafting of manuscript
• AS, JS, NA: Statistical analysis, Interpretation of results, Critical revision
• JS, NA, AS: Supervision, Final approval of manuscript
  All authors have read and approved the final version of the manuscript.

Acknowledgments: The authors thank the clinical and nursing staff of Government Medical College Thiruvananthapuram for their assistance.

1. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, Agrawal A, Adeleye AO, Shrime MG, Rubiano AM, Rosenfeld JV, Park KB. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018 Apr 27;130(4):1080-1097. doi: 10.3171/2017.10.JNS17352. PMID: 29701556.
2. Gururaj G. Epidemiology of traumatic brain injuries: Indian scenario. Neurol Res. 2002 Jan;24(1):24-8. doi: 10.1179/016164102101199503. PMID: 11783750.
3. Maas AIR, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008 Aug;7(8):728–41.
4. Harhangi BS, Kompanje EJ, Leebeek FW, Maas AI. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien). 2008 Feb;150(2):165–75.
5. Chhabra G, Sharma S, Subramanian A, Agrawal D, Sinha S, Mukhopadhyay AK. Coagulopathy as prognostic marker in acute traumatic brain injury. J Emerg Trauma Shock. 2013 Jul;6(3):180-5. doi: 10.4103/0974-2700.115332. PMID: 23960374; PMCID: PMC3746439.
6. Yuan Q, Yu J, Wu X, Sun Y, Li Z, Du Z, et al. Prognostic value of coagulation tests for in-hospital mortality in patients with traumatic brain injury. Sci Rep. 2016;6:38752.
7. Chhabra G, Sharma S, Subramanian A, Agrawal D, Sinha S, Mukhopadhyay AK. Coagulopathy as a prognostic marker in acute traumatic brain injury. J Neurosci Rural Pract. 2013 Jan;4(Suppl 1):S19–23.
8. Epstein DS, Mitra B, Cameron PA, Fitzgerald M, Rosenfeld JV. Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: definition, incidence and outcomes. Br J Neurosurg. 2014;28(4):452–6.
9. Pathak A, Dutta S, Marwaha N, Singh D, Varma N, Mathuriya SN. Change in tissue thromboplastin content of brain following trauma. Neurol India. 2005;53(2):178–81.
10. Greuters S, van den Berg A, Franschman G, Viersen VA, Beishuizen A, Peerdeman SM, et al. Acute and delayed mild coagulopathy are related to outcome in patients with isolated traumatic brain injury. Crit Care. 2011 Jan;15(1):R2.
11. de Oliveira Manoel AL, Neto AC, Veigas PV, Rizoli S. Traumatic brain injury associated coagulopathy. Neurocrit Care. 2015 Feb;22(1):34–44.
12. Stein SC, Spettell C, Young G, Ross SE. Delayed and progressive brain injury in closed-head trauma: radiological demonstration. Neurosurgery. 1993 Jan;32(1):25–30.
13. Talving P, Benfield R, Hadjizacharia P, Inaba K, Chan LS, Demetriades D. Coagulopathy in severe traumatic brain injury: a prospective study. J Trauma. 2009 Nov;66(1):55–61.
14. Kalkan E, Bayir A, Kocak S, Ak A, Erol FS, Akdemir H. Fibrinolytic markers and neurologic outcome in traumatic brain injury. Neurol India. 2006;54(4):363–5.
15. Non-communicable Diseases: County profile (India), World Health Organization, 2014. https://doi.org/10.1371/journal.pone.0157705
16. World Health Organization, Global Status Report on Road Safety, Supporting a Decade of Action, 2013.
17. West KL, Adamson C, Hoffman M. Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. J Neurosurg. 2011 Jan;114(1):9–18.
18. Greuters S, Boer C, Franschman G, Peerdeman SM, Vries GJ, Vries HJ, et al. Acute coagulopathy is associated with progressive hemorrhagic injury in patients with traumatic brain injury. J Neurotrauma. 2012 Jan;29(1):137–42.
19. Lustenberger T, Talving P, Kobayashi L, Barmparas G, Inaba K, Demetriades D. Time course of coagulopathy in isolated severe traumatic brain injury. Injury. 2010 Sep;41(9):924–8.
20. Mitra B, Mori A, Maini A, Churilov L, Chan P, Fitzgerald M, et al. Early prediction of acute traumatic coagulopathy using clinical and laboratory parameters in trauma patients. J Am Coll Surg. 2018 Oct;227(4):453–62.
21. Schochl H, Maegele M, Solomon C, Gorlinger K, Voelckel W. Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med. 2012 Mar;20:15.